These are certain types of tumors, or growths, that need hormones to grow. They can also shrink or disappear if the body's hormone balance is changed. Think of it like how some plants need sunlight to grow; these tumors need specific hormones.
Every report comes from a Lived member, sent anonymously.
Have you tried Lupron (Leuprolide) for Hormone-Dependent Tumors?
Hormone-dependent tumors are growths that start in parts of the body that normally rely on hormones, and that grow faster or shrink when the body's hormone signals change. The best-known examples are cancers. Most breast cancers are fueled by estrogen or progesterone, most prostate cancers by testosterone and related male hormones (androgens), and endometrial cancer, which begins in the lining of the uterus, is closely tied to estrogen. This is an umbrella term rather than a single disease. A breast cancer and a prostate cancer behave very differently, are found in different ways and have different outlooks. What they share is a weak point: because the tumor cells depend on a hormone, lowering that hormone or blocking its effect can slow or stop their growth. That makes hormone therapy a central part of treatment for many people.
Hormones do not cause these cancers on their own. Cancer begins with changes in a cell's genetic material, and hormones then act as fuel for cells that carry the right receptors (the proteins hormones attach to). Age is the strongest shared risk factor, and inherited gene changes, such as BRCA1 and BRCA2 variants for breast cancer or Lynch syndrome for endometrial cancer, raise risk in some families. For breast and endometrial cancer, risk also rises with longer lifetime exposure to estrogen: starting periods early, reaching menopause late, never giving birth or having a first child later, and taking estrogen-containing menopause hormone therapy (estrogen alone carries the clearest link to endometrial cancer). Excess body weight raises estrogen levels after menopause and is linked to endometrial cancer and to breast cancer after menopause. Tamoxifen, a breast cancer medicine, slightly raises the risk of uterine cancer. For prostate cancer, the main risk factors are age, a close relative with the disease and being Black. Having one of these risk factors does not mean someone will develop cancer, and many people who do have none of them.
Each cancer is first found in its own way: a mammogram, breast lump or biopsy for breast cancer; a PSA (prostate-specific antigen) blood test, rectal exam, MRI or biopsy for prostate cancer; and a biopsy of the uterine lining, often prompted by unusual vaginal bleeding, for endometrial cancer. Whether a tumor is hormone dependent is then shown by testing the tumor tissue itself. In breast cancer, the lab checks for estrogen receptors (ER) and progesterone receptors (PR). A tumor with either is called hormone receptor-positive, which describes about 80% of breast cancers. Tumors without these receptors do not respond to hormone therapy, so this one result shapes the whole treatment plan. Prostate cancers are not routinely tested this way, because nearly all of them depend on androgens early in their course, so hormone therapy is expected to work at first. Endometrial tumors can also be tested for hormone receptors. Imaging and other tests then establish the stage, meaning how far the cancer has spread.
Treatment usually combines several approaches. Surgery, radiation and sometimes chemotherapy treat the tumor directly, while hormone therapy (also called endocrine therapy) works on the hormone supply. Hormone therapy works in one of two ways: it lowers the amount of hormone the body makes, or it stops the hormone from acting on the cancer cells. It may be given before surgery to shrink a tumor, after the main treatment to lower the chance the cancer returns, or to control cancer that has spread. Hormone therapy for cancer is different from menopause hormone therapy, which adds hormones rather than reducing them. For hormone receptor-positive breast cancer, the main options are tamoxifen, a pill that blocks estrogen's effect on breast cells; aromatase inhibitors such as anastrozole (Arimidex), which reduce estrogen production after menopause; and medicines or surgery that switch off the ovaries in younger women. Taken for five years or more after surgery, these treatments substantially lower the risk of the cancer returning and of dying from it. Common side effects are hot flashes, night sweats, vaginal dryness and lower sex drive. Aromatase inhibitors often cause joint aches and stiffness and can thin the bones, so bone density is often checked. After menopause, tamoxifen tends to protect bone rather than thin it, but in younger women it can lower bone density. It also slightly raises the risk of blood clots and uterine cancer. For prostate cancer, the core treatment is androgen deprivation therapy (ADT), which lowers testosterone, usually with injections such as leuprolide (Lupron Depot) or occasionally by removing the testicles. ADT is added to radiation for higher-risk cancer that has not spread and is the backbone of treatment when the cancer returns or spreads, often combined with a newer pill that blocks androgens or their production, such as enzalutamide (Xtandi) or abiraterone (Zytiga), or with chemotherapy. It can delay the cancer's growth and lengthen life, but lowering testosterone has wide effects: loss of sex drive and erections, hot flashes, fatigue, weight gain, muscle loss, mood changes and bone thinning that can lead to fractures. These effects grow with longer treatment. Exercise and bone-strengthening medicines can limit some of them. Endometrial cancer is treated mainly with surgery to remove the uterus. Hormone therapy is an option when the tumor cells carry hormone receptors, alongside other treatments chosen by stage. The main hormone medicine is a progestin (a progesterone-like drug), used mostly for advanced cancer or cancer that has come back, and sometimes for early cancer in someone who cannot have surgery or wants to keep the uterus to preserve fertility.
Hormone therapy is often a long commitment. Breast cancer treatment after surgery commonly lasts five years or more, mostly as a daily pill taken at home. Side effects are a common reason people want to stop, and many can be eased by switching to a different medicine or adjusting the plan. Regular checkups and mammograms continue throughout. In prostate cancer, the response is tracked with regular PSA blood tests. A stable or falling PSA suggests the treatment is working, and a rising PSA can be the first sign it is losing effect. When hormone therapy is used long term for prostate cancer that has spread or come back, most cancers eventually stop responding to standard hormone therapy (called castration-resistant cancer), sometimes after many years. Even then, other hormone medicines and further treatments are available, and testosterone-lowering treatment is usually continued alongside them. After ADT stops, sexual and energy effects often improve, though recovery can be incomplete in older men or after long treatment, and bone loss may not fully recover, so bone health often still needs attention. Outlook varies widely with the cancer type and stage. Many people with early hormone-dependent cancer are treated with the aim of cure, while others live for years with cancer that is controlled rather than removed.
See a clinician about a new breast lump or change in the breast, persistent urinary changes or blood in urine or semen, or any vaginal bleeding after menopause or unusual bleeding before it. If hormone therapy side effects are making daily life hard, raise it with your care team rather than stopping on your own. If you are on hormone therapy, report the warning signs your care team has named for your medicine. For tamoxifen, that means calling promptly about any unusual vaginal bleeding, even after treatment has ended, or a painful, swollen leg.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Hormone-Dependent Tumors is like, what's helped you, or ask the community a question.